Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nonparametric test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Nonparametric test. Displaying page 1 of 1.
    EudraCT Number: 2014-004120-21 Sponsor Protocol Number: COX1985 Start Date*: 2016-01-22
    Sponsor Name:FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
    Full Title: CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND CONTROLLED, PHASE III, TO EVALUATE THE USE OF PLATELET RICH PLASMA IN FRONT HYALURONIC ACID IN COXARTHROSIS.
    Medical condition: coxarthrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10058417 Hyaluronic acid PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-009037-14 Sponsor Protocol Number: AUR-OM-201 Start Date*: 2009-02-25
    Sponsor Name:Auris ehf.
    Full Title: A randomised, blinded, phase IIa, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of repeat doses of thymol solution 4% administered to the outer ear canal ...
    Medical condition: Acute Otitis Media
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004980-23 Sponsor Protocol Number: P05134 Start Date*: 2008-05-05
    Sponsor Name:Schering-Plough Farma, Lda.
    Full Title: Double-Blind evaluation of the safety and efficacy of Quadriderme cream (betamethasone dipropionate, clotrimazole and gentamicin sulphate ) compare with betamethasone dipropionate combined with gen...
    Medical condition: Impetiginous Eczema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051890 Eczema impetiginous LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018564-17 Sponsor Protocol Number: FAV00A-IIA Start Date*: 2010-12-30
    Sponsor Name:Farmak International Holding GmbH
    Full Title: A Phase II, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study to evaluate the efficacy and safety of carbabenzpyride in the treatment of uncomplicated in...
    Medical condition: (Uncomplicated) Influenza A
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001107-38 Sponsor Protocol Number: SESCHI.26371 Start Date*: 2008-05-26
    Sponsor Name:Cefak KG
    Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef...
    Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10019167 Hashimoto's thyroiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003150-86 Sponsor Protocol Number: V1.0 Start Date*: 2019-09-20
    Sponsor Name:Royal Cornwall Hospitals NHS Trust
    Full Title: A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses
    Medical condition: Actinic keratoses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008336-85 Sponsor Protocol Number: MO22225 Start Date*: 2009-06-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer
    Medical condition: Epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    9.1 10016180 Fallopian tube cancer LLT
    9.1 10061344 Peritoneal neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) NL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005315-18 Sponsor Protocol Number: HMX3501 Start Date*: 2009-07-21
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A confirmatory, placebo-controlled, randomised, double-blind, single-dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal hydromorphone – naloxone ratio w...
    Medical condition: Moderate to severe chronic non-cancer or cancer pain with opioid induced constipation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    14.0 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) GB (Completed) FR (Completed) NL (Completed) DE (Completed) AT (Completed) BE (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-005558-21 Sponsor Protocol Number: LUM001-401 Start Date*: 2015-03-25
    Sponsor Name:Lumena Pharmaceuticals LLC
    Full Title: A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Primary Sclerosing Cholan...
    Medical condition: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree re...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003611-62 Sponsor Protocol Number: LIB003-003 Start Date*: 2020-03-20
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 with Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy.
    Medical condition: Homozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002912-25 Sponsor Protocol Number: 1VIT15043 Start Date*: 2019-11-18
    Sponsor Name:American Regent, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
    Medical condition: Heart Failure with Iron Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) CZ (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004973-83 Sponsor Protocol Number: S154.3.021 Start Date*: 2007-05-02
    Sponsor Name:Solvay Pharmaceuticals. Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients.
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 15:42:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA